• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

FDA Awards $2M to Phase 2 Trial of Vitamin D for Reducing Risk of SCD Respiratory Complications


The U.S. Food and Drug Administration (FDA) has awarded $2 million to support a Phase 2 clinical trial testing whether daily supplementation of vitamin D reduces the risk of respiratory complications in children and adolescents with sickle cell disease (SCD).

Gary M. Brittenham, MD, a pediatrician and professor at Columbia University Irving Medical Center in New York, was the recipient of the four-year grant.

The ViDAS-2 study will compare the effectiveness of a daily dose of oral vitamin D3 (3,333 IU/day) with a monthly dose (100,000 IU/month) over two years. It is intended to determine if daily supplementation can reduce more rapidly the rate of respiratory events — including respiratory infections, asthma exacerbations, or acute chest syndrome events — and lead to improvements in pulmonary and immune function.

https://www.onescdvoice.com/wp-content/uploads/2020/08/FDA-Awards-2M-to-Phase-2-Trial-of-Vitamin-D-for-Reducing-Risk-of-SCD-Respiratory-Complications.jpg

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close